Devices, digital health, and the technology changing how care is delivered.
Health tech companies made several major funding announcements in July. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in July appeared first on MedCity News .
The future of value-based care will hinge on empowering providers, and specialists in particular, with the data and strategic partnerships to proactively manage patient health beyond traditional clinical settings. The post The Next Phase of Value-Based Care: Why Specialty-Led Models Will Define the Future of Healthcare appeared first on MedCity News .
Hope is a catalyst for scientific ambition. It encourages researchers, clinicians, investors, and innovators to pursue solutions where none currently exist. In oncology, many major breakthroughs begin with the belief that a better answer is possible. The post Hope Is Not a Soft Concept, It’s a Strategic Imperative in Cancer Innovation appeared first on MedCity News .
July has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Aledade, Providence and Whoop named new executives. There were also layoffs at organizations including Novartis, Adventist Health and Wellstar Health System. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News .
Daffodil Health launched an AI-powered solution to help payers manage No Surprises Act disputes by automating claims review, negotiations and arbitration workflows. The post Daffodil Health Launches No Surprises Act Dispute Management Solution appeared first on MedCity News .
CEO Kevin Lobo said the company is working through a backlog of orders and grappling with a supply disruption related to Inari Medical.
The deal to provide a range of imaging and therapeutic technologies to Cleveland Clinic extends the partners’ longtime relationship and follows a recent 10-year pact between Siemens Healthineers and Mayo Clinic.
Caring for patients with ADHD, or those who potentially have ADHD, extends far beyond diagnosis and prescribing. The post The Battles We Face: ADHD From A Patient Perspective, And What Providers Should Know appeared first on MedCity News .
What healthcare needs now is a connected, deeply integrated system of action that works with the system of record to complete work across the enterprise, supported by accountable partners willing to stand behind the outcomes they create. The post Three Ways Distressed Healthcare Must Evolve appeared first on MedCity News .
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its metabolic dysfunction-associated steatohepatitis trailblazer.
Function Health raised $450 million in growth financing from General Catalyst’s Customer Value Fund, just eight months after its $298 million Series B. The lab-testing startup plans to use the capital to expand access to its testing and imaging services. The post Why General Catalyst Is Betting $450M on Function Health’s Preventive Care Push appeared first on MedCity News .
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
MedCity News’ new event for healthcare investors and corporate business development leads — Bullseye — hit the mark when it comes to provocative and thoughtful commentary. Here’s what was said in panels throughout the day. The post We Are Rats; If Pharma Could Be Brave … And Other Bullseye POVs You Won’t Hear at Other Events appeared first on MedCity News .
The FTC and the states of Utah and California sued Hims & Hers, alleging it improperly shared consumers’ health information and misled customers about billing, subscriptions and cancellations. The post Why Hims & Hers Is Embroiled in Yet Another Controversy, This Time with the FTC appeared first on MedCity News .
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.58 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News .
Following a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on founding CEO Fangliang Zhang, Ph.D.
In this episode, Drs. Ami Bhatt and Sanket Dhruva explore how wearables are shaping the future of personalized care.
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors. The post More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients appeared first on MedCity News .
The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue. The post The Code Gets You Paid — The Variant Gets You Treated appeared first on MedCity News .
Rocco De Bernardis, global president for Ottava, gets into the details of what makes the new robotic surgery system different from the competition and how the healthcare giant plans to roll it out.
[Sponsored] A new whitepaper by League highlights examples from collaborations with Baptist Health. The post Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations appeared first on MedCity News .
Medtronic has backed CoreMap to address a critical unmet need in atrial fibrillation treatment.
BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.